問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳耀亮

Recruiting

List

6Cases

2022-01-31 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-05-01 - 2027-06-24

Phase III

Active
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

  • Condition/Disease

    Ischemic Stroke; Ischemic Attack, Transient

  • Test Drug

    錠劑

Participate Sites
12Sites

Recruiting12Sites

2020-06-01 - 2027-12-31

Phase I/II

Active
Phase 1B Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

  • Condition/Disease

    Newly Diagnosed Glioblastoma Multiforme (GBM)

  • Test Drug

    ADI-PEG 20

Participate Sites
6Sites

Recruiting6Sites

2022-01-31 - 2026-03-31

Phase III

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC

  • Condition/Disease

    Locally Advanced Head and Neck Squamous Cell Carcinoma

  • Test Drug

    NBTXR3NBTXR3

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2015-12-01 - 2021-05-20

Phase I/II

A Phase 1b/2 Study of PEP503 (Radioenhancer) with Radiotherapy in Combination with Concurrent Chemotherapy for Patients with Head and Neck Cancer

  • Condition/Disease

    Head and Neck Cancer

  • Test Drug

    PEP503

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

趙坤山
China Medical University Hospital

Division of Hematology & Oncology

2023-05-01 - 2027-06-24

Phase III

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

  • Condition/Disease

    Ischemic Stroke; Ischemic Attack, Transient

  • Test Drug

    Milvexian

Participate Sites
13Sites

Recruiting13Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB